The Latest
-
Photo illustration: Shaun Lucas and Karissa Waddick/Industry Dive; Getty Images
The next era of Greater Boston’s biotech boom
How Boston became the biotech capital of the U.S., and is now preparing for the next era of life sciences growth.
-
Courtesy of Teva Pharmaceutical
Executive changes at Teva, Eversana could spell commercial growth in the new year
With their latest personnel moves, these life sciences companies are preparing for major business shifts.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Myriad Genetics’ Nicole Lambert
Empowered by her own cancer journey, Nicole Lambert is using her platform as chief operating officer of the genetic testing powerhouse to change the trajectory of care for millions of women.
-
Permission granted by Evelina Vågesjö
ProfileHow bacteria-enabled technology for wounds could also help cancer patients
Evelina Vågesjö, co-founder and CEO of the immunotherapy company Ilya Pharma, is working on a new modality to speed wound healing.
-
Stock via Getty Images
Q&AIn cancers with very low survival rates, Sellas aims higher
The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.
-
AndreyPopov via Getty Images
Why the biopharma ‘IPO playbook’ changed in 2022
Biopharma IPOs have puttered in 2022, particularly compared to the record-breaking previous year, but they might be set to rebound.
-
Stock via Getty Images
OpinionHybrid work is here to stay — here’s how leaders should adjust
Executives across the life sciences share their tips for navigating the new norm of remote work.
-
iStock via Getty Images
4 pioneering social media campaigns in pharma this year
The key to a great social media campaign is often simplicity, and these pharma companies hit the nail on the head with unique strategies that aim to educate.
-
ArtemisDiana via Getty Images
Is AI just hype or a real revolution in pharma? It’s complicated
Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.
-
Permission granted by Memorial Sloan Kettering Cancer Center
To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’
A new CRISPR-based tool could help scientists understand and better treat cancer by revealing the complex genetic mutations that occur.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Janssen’s Najat Khan
Janssen’s Najat Khan, Ph.D., chief data science officer and global head of strategy and operations, shares how the company is using next-gen tech to ‘reimagine’ medicine.
-
Meagan Parrish/PharmaVoice
#HLTH: ‘Unicorns are real’ — and here’s how they can navigate a challenging biotech market
Venture capitalists tackle ways companies can stay afloat while the market’s turbulent waters rise.
-
Permission granted by Sana Alajmovic
ProfileA ‘bold vision’ to prevent diabetes
Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts.
-
iStock via Getty Images
4 ways to bring COVID’s ‘warp speed’ to the next era of drug development
An IQVIA Institute for Human Data Science report outlines how companies can improve communication, recruitment, data and investing strategies to accelerate clinical trial timelines.
-
iStock via Getty Images
OpinionWhy the IRA will drive up the country’s drug bill — not lower it
On the surface, the Inflation Reduction Act is designed to lower drug prices, but its impact on innovation incentives could produce a landscape of new medicines that are costlier for patients.
-
Permission granted by Medidata
Q&AThe legacy of Glen de Vries: Our last interview with the pioneering entrepreneur
Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.
-
Baris-Ozer via Getty Images
3 ways pharma can weather a recession
If “winter is coming” in the form of a recession, pharmas can take advantage of an inherent resiliency by crushing these three fundamentals.
-
Permission granted by Lene Oddershede
Q&ANovo Nordisk’s quantum bet on ‘world changing’ computing
Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.
-
Permission granted by Cresilon
ProfileThis plant-based gel stops bleeding in seconds — and might have potential in drug delivery
29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresolin and just inked a research partnership with Walter Reed.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: 82VS’s Trier Bryant
Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Not every leader makes it their mission to go where the fire ...
-
Permission granted by Rami Elghandour
ProfileChasing that ‘Time magazine cover potential’
Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.
-
Amornrat Phuchom via Getty Images
While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help
Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.
-
adamkaz / iStock / Getty Images Plus via Getty Images
What pharma could gain — or lose — from the midterms
With control of the House and Senate both up for grabs, and potentially leaning Republican, here’s what the midterm elections mean for pharma.
-
Stock via Getty Images
After numerous setbacks, here’s where the Huntington’s pipeline stands
A look at emerging treatments and where there’s hope for patients.
-
Stock via Getty Images
Q&AThe other ‘D’ in DE&I
How companies can work to include people with disabilities into broader equity aims.
